Physicians' Academy for Cardiovascular Education
VBWG at ACC 2018 Prof. Gomberg-Maitland gives numerous reasons why cardiologist should be interested in PAH, including updated knowledge on genetics and pathophysiology and interestingly, novel targets for therapy and different therapy strategies.
ESC 2017 Prof. Galiè summarizes new results regarding pulmonary hypertension (PH) that were presented at ESC 2017, separately for each clinical PH group. Treatment options expand and some can improve patient outcomes.
Using the risk assessment instrument proposed by the ESC/ERS guidelines revealed better survival for pulmonary arterial hypertension (PAH) patients who remain at or achieve a low-risk profile in SPAHR trial, and supports goal-oriented treatment.
In this 1st video of a pulmonary arterial hypertension series, Prof. dr. Galiè demonstrates the pathophysiology of PAH and its characteristics, including hemodynamics and assessment of right heart catheterization.
In this 2nd video of a pulmonary arterial hypertension series, Prof. dr. Galiè explains the various clinical PH subgroups that can be distuinguised, their pathology and relation to survival.
In this 3rd video of a pulmonary arterial hypertension series, Prof. dr. Galiè shows the incidence and characteristics of the PH subgroups and its associated risk factors.
In this 4th video of a pulmonary arterial hypertension series, Prof. dr. Galiè lists the symptoms and signs of PH, as well as clinical examinations, and discusses the diagnostic algorithm.
In this 5th video of a pulmonary arterial hypertension series, Prof. dr. Galiè focusses on the behaviour of the 4 functional classes of PAH, including their relation to survival.
In this 6th video of a pulmonary arterial hypertension series, Prof. dr. Galiè elaborates on the risk assessment table and clinical tests that should be performed for adequate diagnosis and follow-up.
In this 7th video of a pulmonary arterial hypertension series, Prof. dr. Galiè tells how to treat PAH patients according to the treatment algorithm and disusses the characteristics and evidence of the available drugs in more detail.
In this 8th video of a pulmonary arterial hypertension series, prof. dr. Galiè mentions further treatment options for non-responsive patients, including transplantation, and the organization of referral centers for most optimal care of patients.
Paul Forfia summarises the available treatment options for pulmonary arterial hypertension and the new strategy of combination therapy. Adjusting medication based on monitoring right ventricular size and function is a new and important treatment goal.
